9 Reporting in Brachytherapy: Dose and Volume Specification

Reporting in Brachytherapy 213

65. Merrick GS, Butler WM, Dorsey AT, et al. Prostatic conformal brachytherapy: 125I/103Pd postoperative dosimetric analysis. Radiat Oncol Invest 1997; 5 : 305-13. 66. Mijnheer BJ, Battermann JJ, Wambersie A. What degree of accuracy is required and can be achieved in photon and neutron therapy? Radiother Oncol 1987; 8 : 237-52. 67. Montana GS, Fowler W. Carcinoma of the cervix: analysis of bladder and rectal radiation dose and complications. Int J Rad Onc Biol Phys 1989; 16 : 95-100. 68. Nag S, Chao S, Erickson B, et al. The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002; 52 (1): 33-48. 69. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee, Task Group N# 43. Med Phys 1995; 22 : 209-34. 70. Neblett D, Nisar Syed AM, Puthawala AA, et al. An interstitial implant technique evaluated by contiguous volume analysis Hypertherm. Oncol 1985; 1 : 213-21. 71. NCRP, National Council on Radiation Protection and Measurements Specification of gamma- ray brachytherapy sources. NCRP Report 41 1974; Bethesda, Maryland. 72. NCS, Netherlands Commission on Radiation Dosimetry Recommendations for Dosimetry and Quality Control of Radioactive Sources Used in Brachytherapy. Netherlands Commission on Radiation Dosimetry, Bilthoven. NCS report 4 1991; 73. Orton C, Rosenblum S. Dose dependence of complication rates in cervix cancer radiotherapy. Int J Rad Onc Biol Phys 1986; 12 : 37-44. 74. Paul JM, Koch RF, Philip PC. Uniform analysis of dose distribution in interstitial brachytherapy dosimetry systems. Radiother Onol 1988; 13 : 105-25. 75. Paterson R, Parker HM. A dosage system for gamma ray therapy. Br J Radiol 1934; 7: 592. 76. Paterson R, Parker HM. A dosage system for interstitial radium therapy. Br J Radiol 1952; 25 : 505-16. 77. Perez CA, Grigsby PW, Lockett MA. Radiation therapy morbidity in carcinoma of the uterine cervix. Dosimetric and clinical correlation. Int J Radiat Oncol Biol Phys 1999; 44 : 855-66. 78. Perez CA, Fox S, Lockett MA, et al. Impact of dose in outcome of irradiation alone in carcinoma of the uterine cervix: Analysis of two different methods. Int J Rad Onc Biol Phys 1991; 21 : 885-98. 79. Petereit DG, Pearcey R. Literature analysis of high dose rate brachytherapy fractionation schedules in the treatment of cervical cancer: Is there an optimal fractionation schedule? Int J Radiat Oncol Biol Phys 1999; 43 : 359-66. 80. Pierquin B. Précis de Curiethérapie. Endocuriethérapie et Plésiocuriethérapie 1964; Masson Paris. 81. 81.Pierquin B, Dutreix A, Paine C, et al. The Paris System in intersttial radiation therapy. Acta Radiol Oncol 1978; 17 : 33-47. 82. Pierquin B, Wilson JF, Chassagne D. Modern brachytherapy 1987; Masson Publishing USA. 83. Potish RA, Gerbi BJ. Role of point A in the era of computed dosimetry. Radiology 1986; 158 : 827-31. 84. Pourquier H, Dubois JB, Delard R. Radiation therapy of cervical cancer with dosimetric prevention of late pelvic complications. Bull Cancer Radiother 1996; 83 : 135-43. 85. Pourquier H, et al. A quantified approach of the analysis and prevention of urinary complications in radiotherapeutic treatment of cancer of the cervix. Int J Radiat Onc Biol Phys 1987; 13: 1025-33. 86. Pötter R, Van Limbergen E, Dries W, et al. Recommendations of the EVA GEC ESTRO Working Group : Prescribing, recording and reporting in endovascular brachytherapy. Quality assurance, equipment, personnel and education. Radiother Oncol 2001; 59 : 339-60. 87. Pötter R, Van Limbergen E, Gerstner N, Wambersie A. Survey of the use of the ICRU 38 in recording and reporting cervical cancer brachytherapy. Radiother Oncol 2001; 58 : 1-4. 88. Pötter R, Knocke TH, Fellner C, et al. Definitve radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings